Table 4.
Association of Genotype with Overall Survival
| Training Set |
Validation Set |
Combined dataset |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | No. of Patients /No. of Deaths |
MST | HR (95% CI) † | P | No. of Patients /No. of Deaths |
MST | HR (95% CI) † | P | MST | HR (95% CI) † | P |
| GCK IVS1+9652C>T | |||||||||||
| CC | 111/82 | 26.2 | 1.0 | 380/313 | 16.0 | 1.0 | 17.8 | 1.0 | |||
| CT | 39/32 | 19.8 | 1.56 (1.03–2.38) | .03 | 149/117 | 16.0 | 1.08 (0.87–1.34) | .48 | 16.9 | 1.10 (0.90–1.33) | .35 |
| TT | 2/2 | 5.5 | 18.0 (3.63–89.5) | <.001 | 20/19 | 7.1 | 2.61 (1.61–4.21) | <.001 | 7.1 | 2.69 (1.71–4.22) | <.001 |
| CC vs. CT/TT | 1.61 (1.06–2.45) | .026* | |||||||||
| GFPT1 IVS14-3094T>C | |||||||||||
| TT | 113/85 | 23.9 | 1.0 | 367/295 | 16.9 | 1.0 | 18.0 | 1.0 | |||
| TC | 39/31 | 21.5 | 0.84 (0.54–1.32) | .46 | 152/129 | 13.9 | 1.26 (1.02–1.55) | .03 | 16.0 | 1.25 (1.03–1.50) | .022 |
| CC | 2/2 | 4.9 | 7.64 (1.69–34.6) | .008 | 23/20 | 11.9 | 1.46 (0.91–2.33) | .12 | 11.9 | 1.57 (1.01–2.45) | .045 |
| TT vs. TC/CC | 0.96 (0.61–1.49) | .84* | |||||||||
| GPI IVS9+2363C>G | |||||||||||
| CC | 104/86 | 21.2 | 1.0 | 378/309 | 15.1 | 1.0 | 16.5 | 1.0 | |||
| CG | 43/29 | 27.5 | 0.61 (0.39–0.94) | .027 | 147/120 | 16.4 | 0.88 (0.71–1.09) | .25 | 17.8 | 0.85 (0.70–1.03) | .09 |
| GG | 6/2 | _‡ | 0.11 (0.03–0.48) | .003 | 23/18 | 22.9 | 0.60 (0.36–0.99) | .049 | 27.8 | 0.51 (0.32–0.83) | .006 |
| CC vs. CG/GG | 0.53 (0.34–0.84) | .007* | |||||||||
| GPI G163G | |||||||||||
| AA | 125/98 | 21.2 | 1.0 | 489/403 | 15.2 | 1.0 | 16.4 | 1.0 | |||
| GA | 26/19 | 28.7 | 0.56 (0.34–0.93) | .02 | 59/45 | 20.5 | 0.80 (0.58–1.09) | .16 | 22.0 | 0.77 (0.59–1.02) | .06 |
| GG | 3/1 | _‡ | 0.21 (0.03–1.61) | .13 | 4/2 | 33.7 | 0.32 (0.08–1.33) | .12 | 33.7 | 0.31 (0.10–0.99) | .048 |
| AA vs. GA/GG | 0.52 (0.31–0.86) | .01* | 0.75 (0.55–1.03) | .07* | 0.73 (0.56–0.96) | .02* | |||||
| HK2 N692N | |||||||||||
| TT | 79/49 | 45.1 | 1.0 | 189/143 | 21.4 | 1.0 | 25.1 | 1.0 | |||
| TC | 59/53 | 17.6 | 1.94 (1.24–3.03) | .004 | 255/218 | 15.1 | 1.26 (1.01–1.57) | .037 | 15.3 | 1.39 (1.15–1.69) | .001 |
| CC | 16/16 | 8.3 | 5.62 (2.67–11.8) | <.001 | 108/89 | 12.0 | 1.80 (1.36–2.38) | <.001 | 11.6 | 2.01 (1.55–2.61) | <.001 |
| HK2 L766L | |||||||||||
| GG | 72/54 | 25.7 | 1.0 | 195/155 | 16.4 | 1.0 | 18.2 | 1.0 | |||
| GA | 60/50 | 16.9 | 1.66 (1.10–2.48) | .01 | 291/242 | 15.0 | 1.29 (1.05–1.58) | .01 | 15.7 | 1.29 (1.08–1.55) | .006 |
| AA | 22/14 | 38.5 | 0.71 (0.38–1.30) | .27 | 66/53 | 16.9 | 1.10 (0.80–1.50) | .57 | 18.7 | 0.97 (0.73–1.29) | .85 |
| HK2 R844K | |||||||||||
| GG | 80/67 | 16.9 | 1.0 | 356/297 | 14.2 | 1.0 | 14.6 | 1.0 | |||
| GA | 61/45 | 27.8 | 0.69 (0.46–1.04) | .07 | 182/144 | 18.9 | 0.77 (0.61–0.96) | .02 | 20.5 | 0.76 (0.62–0.93) | .008 |
| AA | 13/6 | _‡ | 0.38 (0.15–0.93) | .03 | 14/9 | 48.5 | 0.31 (0.16–0.63) | .001 | 84.3 | 0.37 (0.21–0.63) | <.001 |
MST, median survival time (months); HR: hazard ratio; CI, confidence interval
†
HR values were from multivariable Cox regression models including sex, race, tumor resection, CA19-9, performance status, biochemical index and stage when appropriate.
‡
MST can not be calculated.
*
When the number of sample is less than 10, homozygous and heterozygous mutants were combined.